Add To Watchlist
Share URL
AstraZeneca PLC
AZN.L: LSELowest reading is at 6 out of 100. All scores are out of 100.
About The Company
CEO
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Market Cap
194.67 Billion GBp
Sector
Healthcare
Website
https://www.astrazeneca.comLast Update
26/09/2026, 10:15:51
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Read More
Strongest readings
- ✔Cashflow and earnings growth is strong (growth score 79 out of 100)
- ✔Return on capital employed of 16.47% is above the market average of 10.00%
- ✔Dividend growth averages 5.35% per year
- ✔Debt is low at 0.57 times equity
Weakest readings
- ✘Priced well above the cashflow it produces (value score 6 out of 100)
- ✘Share count has been rising at 3.39% per year
- ✘The current price sits above estimated fair value (margin of safety -64.98%)
- ✘Short-term liabilities exceed short-term assets (current ratio 0.94)
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
Price / earnings (TTM) | N/A | 19.60x | ||
| ✘ | Margin of safety (DCF) | -64.98% | 17.95% | |
| ✔ | Revenue growth (5y average) | 18.03% | 10.97% | |
| ✔ | Dividend yield (TTM) | 1.90% | 1.85% | |
| ✘ | Share count, per year | 3.39% | 0.00% | |
| ✔ | Return on capital employed | 16.47% | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
6 / 100Priced above the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
Price / earnings | N/A | 19.60x | ||
| ✘ | Free cashflow yield | 2.34% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 386.48x | — | ||
| ✘ | Margin of safety | -64.98% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Estimated intrinsic value of 4.40 Thousand GBp is below the current price of 12.55 Thousand GBp
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: 115.2 GBp ✘
Current Price: 12552 GBp
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
79 / 100Growing faster than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Revenue growth | 18.03% | 10.97% | |
| ✔ | Earnings growth | 45.37% | 14.48% | |
| ✔ | Cashflow growth | 18.40% | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Free cashflow growth has improved this year
Health
59 / 100Balance sheet covers its obligations.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| ✘ | Altman-Z score | 1.05 | 3.00 | |
| ✔ | Piotroski score | 8.00 | 5.00 | |
| ✔ | Debt / equity | 0.57x | 0.80x | |
| ✘ | Current ratio | 0.94x | 1.00x | |
| ✔ | Interest coverage | 8.11x | 2.50x | |
| ✔ | Free cashflow / debt | 0.42x | 0.15x | |
| ✔ | Debt / capital | 0.36x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Dividend
69 / 100Covered, with limited headroom.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Dividend yield | 1.90% | 1.85% | |
| ✔ | Dividend growth | 7.39% | 0.00% | |
| ✘ | Payout ratio (earnings) | 46.93% | 40.00% | |
| ✘ | Payout ratio (cashflow) | 81.11% | 65.00% | |
| ✔ | Worst year, last 5 years | -0.12% | -2.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Dividend growth has been accelerating recently
Management
69 / 100Returns on capital are at or above the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Return on equity | 21.01% | 15.00% | |
| ✔ | Return on capital employed | 16.47% | 10.00% | |
| Return on assets | 8.96% | — | ||
| Free cashflow return on capital | 14.10% | — | ||
| ✔ | Return on capital, 5y change | 8.60% | 0.00% | |
| ✘ | Share count, per year | 3.39% | 0.00% | |
| ✘ | Share count, recent | 0.06% | 0.00% | |
| Realized buyback return | N/A | 0.00% | ||
| ✔ | Goodwill erosion / equity | 0.36% | 2.00% | |
| Price volatility, 5 year | 23.50% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔New shares were issued while the value score was 6 out of 100
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
AZN.L
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
AstraZeneca PLC
Currency
GBp
Beta
0.205
Vol Avg
3362622
Ceo
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Cik
Cusip
Exchange
LSE
Full Time Employees
96100
Industry
Drug Manufacturers - General
Sector
Healthcare
Ipo Date
Address
1 Francis Crick Avenue
City
Cambridge
State
Country
United Kingdom
Zip
CB2 0AA
Phone
44 20 3749 5000
Analysis Last Updated
26/09/2026, 10:15:51
Financial data compiled from SEC EDGAR filings and Yahoo Finance.